ArticleScientific reports2026

Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.

Shingo Maeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.